408 citations
,
May 2004 in “The Journal of clinical endocrinology and metabolism/Journal of clinical endocrinology & metabolism” Dutasteride more effectively lowers DHT levels in men with enlarged prostates than finasteride.
149 citations
,
January 2011 in “Nature reviews. Urology” Hormonal interactions, especially involving DHT and estrogen, play a key role in BPH development and treatment.
54 citations
,
May 2015 in “Endocrinology” Manipulating 5α-reductase type 2 can affect liver fat production and glucocorticoid effects.
41 citations
,
February 2021 in “Cureus” Dutasteride treatment in men with mild to moderate COVID-19 reduced viral shedding, inflammation, and recovery time without serious side effects.
30 citations
,
June 2010 in “Endocrine Related Cancer” SRD5A1 is crucial in advanced prostate cancer, and blocking both SRD5A1 and SRD5A2 is more effective than targeting SRD5A2 alone.
17 citations
,
January 2020 in “The World Journal of Men's Health” Long-term use of finasteride and dutasteride can cause serious health issues like diabetes and liver problems.
16 citations
,
November 2018 in “The journal of pain/Journal of pain” 14,15-EET may help reduce poststroke pain by affecting certain brain proteins.
4 citations
,
August 2021 in “Biomedicine & Pharmacotherapy” 5-alpha reductase inhibitors, like finasteride and dutasteride, may cause depression, but more research is needed to understand why.
2 citations
,
April 2024 in “Journal of Clinical Psychopharmacology” Dutasteride helps reduce heavy drinking, especially for those who drink to cope.
1 citations
,
March 2023 in “Scientific Reports” Finasteride may increase the risk of suicide or severe self-harm in men with mood disorders but not in the general population.
1 citations
,
August 2022 in “Biomedicines” Dutasteride, usually used for prostate issues and hair loss, could potentially treat Amyotrophic Lateral Sclerosis (ALS) due to its neuroprotective, antioxidant, and anti-inflammatory properties, but more testing is needed.
February 2026 in “American Journal of Clinical Dermatology” Spironolactone is effective for treating female hair loss, with new treatments like clascoterone showing promise.
August 2025 in “ACS Omega” New compounds show promise as nonsteroidal treatments for hair loss.
July 2025 in “International Journal of Dermatology” Topical finasteride may be safer than oral finasteride, but more research is needed.
February 2024 in “Biomedicines” Hormones like androgens, estrogen, thyroid hormones, and stress hormones can contribute to hair loss, and treatments target these hormonal imbalances.
September 2023 in “Forum Dermatologicum” Various treatments for common hair loss in men and women are effective, but should be tailored to individual needs and potential side effects.
April 2023 in “Dermatologica Sinica” Sex hormones affect hair growth and loss, and treatments for related hair diseases include various medications, hair transplantation, and light therapy.
September 2021 in “Clinical research in dermatology” 5-Alpha-Reductase inhibitors might help slow down hair loss in Frontal Fibrosing Alopecia but are not a primary treatment and need more research.
15 citations
,
February 2017 in “International Journal of Women's Dermatology” Hair aging and loss are caused by genetics, hormones, environment, and grooming, with treatments like minoxidil effective for certain types of hair loss.
Most American men experience hair loss by age 50, with limited effective treatments available and new options not expected soon.
42 citations
,
August 2013 in “International Journal of Women's Health” Female pattern hair loss is caused by multiple factors and while treatments like topical minoxidil, hormone therapy, and low-level light therapy can help, none can fully cure it.
15 citations
,
July 2016 in “Urologic Clinics of North America” Finasteride and dutasteride are effective for long-term treatment of enlarged prostates but have sexual side effects and a risk of high-grade prostate cancer.
3 citations
,
January 2001 in “Cambridge University Press eBooks” Finasteride effectively treats hair loss and enlarged prostate in men, with mild side effects.
40 citations
,
April 2018 in “Endocrine” PFS and PSSD are similar conditions with persistent sexual dysfunction after stopping medication.
7 citations
,
September 2020 in “Journal of Cosmetic Dermatology” Minoxidil and Finasteride are the most popular hair loss treatments, with rising interest in other options, and economic or health crises can change what treatments people prefer.
3 citations
,
February 2016 in “Nature Biotechnology” New drug shows promise for better hair growth in baldness treatment.
March 2024 in “Cleveland Clinic journal of medicine” Alpha-blockers and 5-alpha reductase inhibitors are main treatments for BPH, with new support for phosphodiesterase-5 inhibitors and beta-3 agonists.
April 2019 in “Advances in Cosmetic Surgery” The document concludes that ongoing medical therapy is crucial for preventing hair loss, and surgical options can restore hair, with future treatments for hair loss being promising.
26 citations
,
December 2019 in “Neurobiology of Stress” Post-finasteride syndrome causes lasting sexual, neurological, and physical side effects in some people after taking finasteride.
16 citations
,
May 2013 in “Urology” Metabolic syndrome linked to urinary symptoms; hair loss not significant.